Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

What Was Tested

This registered phase 4 trial tested Tirzepatide.

HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and E/e' in AF patients.

It had two arms (groups): Tirzepatide + Lifestyle Intervention (experimental) and Lifestyle Intervention (active comparator).

Participants receive guideline-directed standard care for AF, anticoagulation, and HFpEF, without any GLP-1 receptor agonist or GIP/GLP-1 dual agonist. The same structured lifestyle intervention as the experimental arm is delivered, including monthly dietitian-led counseling, exercise prescription, and sleep apnea screening, to ensure equal follow-up intensity.

The registry classes the interventions as behavioral and drug.

More on the Plan

Background and Rationale: Obesity and HFpEF are key drivers of AF onset and recurrence.

Eligible patients are randomized 1:1 within 48 hours of ablation, stratified by site, AF type (paroxysmal vs persistent), and BMI.

Control arm: standard care without GLP-1 class drugs.

Both arms receive identical structured lifestyle intervention (≥150 min/week moderate aerobic activity, sleep apnea screening), and standard-of-care guideline-directed therapies for AF, anticoagulation, and HFpEF.

Who Took Part

Enrollment: 602 planned participants were the target.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age 18 to 80 years. Symptomatic atrial fibrillation (paroxysmal or persistent of ≤ 5 years duration), undergoing first-time catheter ablation. Body weight criteria (aligned with NMPA-approved tirzepatide indication)，meeting at least one of the following:. BMI ≥28.0 kg/m² (obesity threshold per Chinese criteria), OR. HFpEF defined by intraprocedural mean left atrial pressure ≥ 15 mmHg at rest.

The full record lists 8 inclusion and 13 exclusion criteria; among the exclusions: prior use of any glp-1 receptor agonist or gip/glp-1 dual receptor agonist; personal history of pancreatitis; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (men2); severe gastrointestinal disease, including gastroparesis or active inflammatory bowel disease.

How the Study Was Run

The set-up was randomized, parallel-group and single-blind.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The Tirzepatide group and the comparison group ran side by side rather than switching.

In this single-blind Tirzepatide study one party knew the assignments and the other did not.

Those kept unaware of assignments: outcomes assessor.

It started in 2026-08-01 with completion listed for 2029-08-01.

It ran at 1 site in China.

Its stated primary purpose is prevention.

What Was Measured

Primary outcome: Number of Participants With Recurrence of atrial fibrillation, atrial flutter, or atrial tachycardia (time frame: Day 91 through Week 52 after catheter ablation).

It also tracked 12 secondary outcomes, for example Percentage of Monitoring Time Spent in AF (AF Burden), Change in body weight, Change in body mass index (BMI), Change in waist circumference, Change in left atrial volume index (LAVI) and Change in Echocardiographic E/e' Ratio.

What This Means in Plain Language

Put simply, this is a phase 4, randomized trial of Tirzepatide in 602 people.

With 602 participants it is a large trial for this field.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.